.svg)
Characteristics, effectiveness & side effects of modern weight loss medication
Semaglutide, available as Ozempic and Wegovy, offers a new approach to managing diabetes and aiding weight loss by mimicking GLP-1, a natural hormone. It's most effective alongside a healthy lifestyle, with minimal side effects like nausea. Suitable for individuals with obesity or at risk, it requires medical assessment for optimal use.
In the rapidly changing world of weight loss solutions, semaglutide, available under the names Ozempic and Wegovy, stands out as a remarkable choice. This blog article explores the rise of these medications and provides insight into the characteristics, effectiveness, and potential side effects of this modern approach to weight loss and diabetes management.
How it works
Semaglutide, the active ingredient in both Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) analogue. This hormone is naturally present in the body and is involved in regulating blood sugar levels. Although initially developed for the treatment of type 2 diabetes mellitus, its benefits in aiding weight loss have led to its approval for the treatment of overweight and obesity. Ozempic and Wegovy pens include the same medicine and are hence both approved for the treatment of type-2 diabetes, overweight and obesity.
Ozempic and Wegovy are administered via subcutaneous injections, with the needle length typically standard at about 5 millimeters, akin to the size of a matchstick.
Is Ozempic a miracle cure?
While semaglutide-based medications like Ozempic and Wegovy are considered advanced tools for weight loss, it is crucial to understand that their effectiveness is significantly enhanced when combined with a healthy lifestyle. Adopting healthy eating habits, regular physical activity, and other wellness practices play an essential role in achieving optimal results.
Side effects of Ozempic and Wegovy
The side effects of semaglutide, are generally minimal and mild, often occurring at the beginning of treatment. Symptoms may include nausea, flatulence and diarrhea, abdominal pain, or constipation, which can often be mitigated with the guidance of a dietitian.
How do I qualify for Ozempic and Wegovy?
Semaglutide medications are recommended for individuals with obesity or those overweight with additional risk factors. It is the responsibility of the treating healthcare provider to assess the needs of each patient, ensuring appropriate treatment based on scientific evidence and clinical experience.
Would you like more information about (similar) weight loss medications? View our articles here or sign up to get in touch with one of our nurses.
Disclaimer:
This information is for educational purposes only and should not be considered medical advice. Always consult a doctor or nurse before starting Ozempic or any other medication.
References
Weight loss with semaglutide:
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?query=featured_home
Authors: Wadden, T. A., Bailey, C. J., Blonde, L., et al. (2021). Results of weight loss with semaglutide treatment for overweight or obese patients. The New England Journal of Medicine, 384(1), 73-84.
Authors: Lean, M. E. J., Leslie, W. S., Barnes, A. C., et al. (2020). The efficacy and safety of semaglutide for weight loss in adults with overweight or obesity. The Lancet, 395(10223), 758-766.
Authors: Garvey, W. T., Henry, R. R., Apovian, C. M., et al. (2020). Semaglutide for weight loss in adults with overweight or obesity: a randomized, placebo-controlled phase 3 study. The Journal of the American Medical Association, 323(23), 2333-2343.
Authors: Marso, S. P., Bain, S. C., Bray, G. A., et al. (2020). Effects of semaglutide on weight loss, cardiovascular risk factors, and glycaemic control in adults with overweight or obesity. Diabetes Care, 43(12), 2912-2921.
Authors: Schauer, P. R., Bhatt, D. L., Kirwan, B. A., et al. (2021). A long-term study on the safety and efficacy of semaglutide for weight loss in adults with overweight or obesity. Obesity, 29(1), 121-131.
February 7, 2024
August 22, 2025
More articles
Modern medical treatment of overweight and obesity with GIP and GLP-1 analogues – What happens in your body
Obesity is now one of the world’s greatest public health challenges. According to the WHO, more than 1 billion people worldwide have obesity, including over 650 million adults and 340 million children and adolescents. The prevalence has more than tripled since 1975 and continues to rise in almost every part of the world.
Having severe overweight or obesity is not only about body weight but about health. A high proportion of body fat increases the risk of many different diseases, such as type 2 diabetes, cardiovascular disease, osteoarthritis and certain types of cancer (1).
Understanding the Far-Reaching Risks of Obesity in Men: A Comprehensive Overview
Obesity in men is more than a weight issue — it’s a complex medical condition with far-reaching health risks. From heart disease and liver problems to hormonal and psychological effects, understanding these connections is key to effective prevention and management.
Ozempic (semaglutide) in the treatment of obesity
Ozempic is a prescription medicine containing semaglutide as its active substance. This medicine was originally approved for the treatment of type 2 diabetes, but has since also been shown to contribute to clinically significant weight loss. Semaglutide has demonstrated significant improvements in body weight and metabolic markers in studies involving individuals with overweight or obesity. To make an informed decision about treatment, it is important that the person receives accurate information about how Ozempic works, who it is suitable for, and how it may affect long-term health (1,2).
